RT Journal Article
T1 Characterization of inhibitor-resistant TEM beta-lactamases and mechanisms of fluoroquinolone resistance in Escherichia coli isolates
A1 Ríos Dueñas, Esther
A1 López Díaz, María Carmen
A1 Rodríguez-Avial Infante, Iciar
A1 Pena, Irene
A1 Picazo De La Garza, Juan José
AB The aim of present work was to characterize the inhibitor-resistant TEM (IRT) β-lactamases produced by Escherichia coli in Hospital Clínico San Carlos (Madrid, Spain). Mechanisms of fluoroquinolone resistance among IRT-producing strains were also studied. Isolates with susceptibility to cephalosporins and amoxicillin–clavulanate (AMC) resistance were collected in our hospital (November 2011–July 2012) from both outpatients and hospitalized patients. Among 70 AMC-resistant E. coli strains, 28 (40%) produced IRT enzymes. Most of them were uropathogens (82.1%) and recovered from outpatients (75%). Seven different IRT enzymes were identified with TEM-30 (IRT-2) being the most prevalent, followed by TEM-40 (IRT-11). A high rate of ciprofloxacin resistance was found among IRT-producing strains (50%). Most of the ciprofloxacin-resistant isolates showed ciprofloxacin minimum inhibitory concentration >32 mg/L and contained two mutations in both gyrA and parC genes. Four IRT enzyme producers harbored the qnr gene. ST131 clone was mainly responsible for both IRT enzyme production and ciprofloxacin resistance. In conclusion, data from this study show that the frequency of IRT producers was 40% and a high rate of ciprofloxacin resistance was found among IRT-producing isolates. Current and future actions should be taken into account to avoid or reduce the development of AMC and fluoroquinolone resistance in E. coli.
PB Mary Ann Liebert
SN 1076-6294
YR 2015
FD 2015-10-02
LK https://hdl.handle.net/20.500.14352/112737
UL https://hdl.handle.net/20.500.14352/112737
LA spa
NO Ríos, Esther, et al. «Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia Coli Isolates». Microbial Drug Resistance, vol. 21, n.o 5, octubre de 2015, pp. 512-15. DOI.org (Crossref), https://doi.org/10.1089/mdr.2015.0039.
NO Ministerio de Sanidad (España)
DS Docta Complutense
RD 12 abr 2025